Curocell
Korea - DaejonBiotechnology
Focus: Curocell is a Korean biotechnology company focused on CAR-T cell therapy for oncology and autoimmune indications. The company operates at a mid-stage biotech scale with 51-200 employees and is based in Daejeon.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Employees
51-200
Open Jobs
0
About Curocell
AI assessmentNot HiringNo open roles listed right now. Follow Curocell to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
CRC01
Lupus NephritisClinical Trials (1)
NCT07364396Efficacy and Safety of CRC01 in Participants With Severe, Refractory Systemic Lupus Erythematosus
Phase 1/2Help build intelligence for Curocell
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.